原发性输尿管肿瘤行保留肾脏治疗的临床分析

王建文; 康宁; 宋黎明; 张军晖; 牛亦农; 田溪泉; 蒋宇光; 邢念增

doi:10.13201/j.issn.1001-1420.2015.10.015

原发性输尿管肿瘤行保留肾脏治疗的临床分析

- 北京朝阳医院泌尿外科(北京, 100020)

详细信息

通讯作者: 邢念增,E-mail:nianzengxing2006@sina.cn

中图分类号: R737.14

收稿日期: 2014-12-20

Clinical study on kidney-sparing surgery in treating the primary transitional cell carcinoma of ureter

- Department of Urology, Beijing Chaoyang Hospital, Beijing, 100020, China

More Information

Corresponding author: XING Nianzeng, E-mail: nianzengxing2006@sina.cn

Received Date: 20 December 2014

摘要

摘要: 目的:探讨原发性输尿管肿瘤行保留肾脏治疗的疗效和安全性。方法:回顾性分析了29例输尿管癌患者保肾治疗的临床资料,输尿管镜下肿物切除术3例,腹腔镜下段输尿管肿瘤切除直接膀胱再吻合5例,中段肿瘤切除行膀胱翻瓣术3例, 开放手术行肿瘤切除后输尿管膀胱直接再吻合10例,膀胱翻瓣术5例,输尿管端端吻合3例。术后均行膀胱灌注化疗,3例行全身化疗。结果:病理均为移行细胞癌。分级:低度恶性倾向乳头状瘤4例,低分级乳头状尿路上皮癌13例,高分级12例。临床分期:T₁ 5例,T₂ 18例,T₃ 6例。术后膀胱癌发生率10.3%(3/29),同侧上尿路癌复发3.4%(1/29),尿漏2例,轻度肾积水5例,3例术后死于心肺疾病。在低级别肿瘤,膀胱癌复发率5.9%(1/17),在T₁期5例中未见复发,T₂期18例中膀胱癌和同侧上尿路癌复发率11.1%(2/18),T₃期6例中膀胱癌复发率33.3%(2/6)。结论:保留肾脏术式可以选择性用于单发、低级别或术前影像低分期的中下段输尿管肿瘤,输尿管镜和腹腔镜手术都需加强密切随访。
- 输尿管癌 /
- 保留肾脏手术
Abstract: Objective:To evaluate the clinical safety and efficacy of kidney-sparing surgery in treating the primary transitional cell carcinoma of ureter.Method:The data of 29 cases who underwent kidney-sparing surgery for treatment of the carcinoma of ureter were analyzed retrospectively. There were three cases undergoing endoscopic ablation, eight cases undergoing laparoscopy (five direct ureterocystoneostomies, three reimplantations on Boari flap bladder), 18 cases undergoing open surgeries (ten direct ureterocystoneostomies,five reimplantations on Boari flap bladder, and three end-to-end anastomoses). All the patients received regular intravesical instillation, and three of them also received intravenous chemotherapy.Result:All the pathology were transitional cell carcinoma, including four papillary urothelial neoplasms of low malignancy, 13 low-grade papillary urothelial carcinoma, and 12 high-grade papillary urothelial carcinoma. Clinical Stage was classified T₁ 5, T₂ 18 and T₃ 6. The recurrence in bladder and ipsilateral upper ureter was 10.3% and 3.4%, respectively. Two cases suffered from urine leak, and five cases had mild hydronephrosis. Moreover, three cases died of heart and lung diseases. The recurrence in bladder was 5.9% in low-grade tumors, and the recurrence in bladder and ipsilateral ureter was 11.1% in T₂ tumors, 33.3% in T₃ tumors.Conclusion:Kidney-sparing surgery is a feasible treatment option for the selected patients with unifocal middle or distal ureteric carcinoma at low grade or without invasive aspect on CT. Laparoscopic ureterocystoneostomy or endoscopic management has more minimally invasive advantages in the treatment. However, a close follow-up is recommended.
- ureter carcinoma /
- kidney-sparing surgery

HTML全文

参考文献(14)

[1]	Colin P, Ouzzane A, Pignot G, et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract:results from a large French multicentre study[J]. BJU Int, 2012, 110(8):1134-1141.
[2]	张继伟, 王海涛, 王建军, 等. 保留肾脏术式治疗原发性输尿管癌临床分析[J]. 首都医科大学学报, 2012, 33(5):586-589.
[3]	Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas:2013 update[J]. Eur Urol, 2013, 63(6):1059-1071.
[4]	Montie J E, Clark P E, Eisenberger M A, et al. Bladder Cancer[J]. J Natl Compr Canc Netw, 2009, 7(1):8-39.
[5]	Rai B P, Shelley M, Coles B, et al. Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC):a systematic review[J]. BJU Int, 2012, 110(10):1426-1435.
[6]	Ho K L, Chow G K. Ureteroscopic resection of upper-tract transitional-cell carcinoma[J]. J Endourol, 2005, 19(7):841-848.
[7]	Box G N, Lehman D S, Landman J, et al. Minimally invasive management of upper tract malignancies:renal cell and transitional cell carcinoma[J]. Urol Clin North Am, 2008, 35(3):365-383.
[8]	王小波, 李健, 冯起庆, 等. 早期输尿管癌保肾手术的临床疗效分析(附15例报告)[J]. 临床泌尿外科杂志, 2013, 28(7):520-523.
[9]	Cutress M L, Stewart G D, Wells-Cole S, et al. Long-term endoscopic management of upper tract urothelial carcinoma:20-year single-center experience[J]. BJU Int, 2012, 110(11):1608-1617.
[10]	Park B H, Jeon S S. Endoscopic management of upper urinary tract urothelial carcinoma[J]. Korean J Urol, 2013, 54 (7):426-432.
[11]	钟伟, 武程. 关于高龄原发输尿管癌手术方式的探讨[J]. 中国医药导刊, 2012, 14(8):1326-1328.
[12]	Simforoosh N, Mosapour E, Maghsudi R. Laparoscopic ureteral resection and anastomosis for management of low-grade transitional-cell carcinoma[J]. J Endourol, 2005, 19 (3):287-289.
[13]	Rouprêt M, Harmon J D, Sanderson K M, et al. Laparoscopic distal ureterectomy and anastomosis for management of low-risk upper urinary tract transitional cell carcinoma:preliminary results[J]. BJU Int, 2007, 99(3):623-627.
[14]	Simonato A, Varca V, Gregori A, et al. Elective segmental ureterectomy for transitional cell carcinoma of the ureter:long-term follow-up in a series of 73 patients[J]. BJUI, 2012, 110 (11 Pt B):E744-749.